Meheus Filip, Boelaert Marleen, Baltussen Rob, Sundar Shyam
Institute of Development Policy and Management, University of Antwerp, Antwerp, Belgium.
Trop Med Int Health. 2006 Nov;11(11):1715-24. doi: 10.1111/j.1365-3156.2006.01732.x.
To identify and quantify the direct and indirect economic cost of treatment for visceral leishmaniasis (VL) with conventional Amphotericin B deoxycholate, currently the first-line treatment in Muzaffarpur.
Costs of patient management for VL were estimated from a societal and household perspective by means of a questionnaire designed for this study, interviews and financial reports.
The total cost of care per episode of VL from the societal perspective was estimated at US$355, equivalent to 58% of annual household income. The largest cost category was medical costs (55%), followed by indirect costs (36%) and non-medical costs (9%). The cost from the household perspective was equivalent to US$217. The largest cost category was indirect costs (59%), followed by medical costs (27%) and non-medical costs (15%). Loss of income because of illness and hospitalization and expenses for drugs were the largest cost components.
The economic costs related to VL are substantial, both to society and the patient. Public health authorities in Bihar should focus on policies that detect VL in the early stage and implement interventions that minimize the burden to households affected by VL.
确定并量化使用传统两性霉素B脱氧胆酸盐治疗内脏利什曼病（VL）的直接和间接经济成本，目前在穆扎法尔布尔这是一线治疗方法。
通过为本研究设计的问卷、访谈和财务报告，从社会和家庭角度估算VL患者管理的成本。
从社会角度来看，每例VL护理的总成本估计为355美元，相当于家庭年收入的58%。最大的成本类别是医疗成本（55%），其次是间接成本（36%）和非医疗成本（9%）。从家庭角度来看，成本相当于217美元。最大的成本类别是间接成本（59%），其次是医疗成本（27%）和非医疗成本（15%）。因病和住院导致的收入损失以及药品费用是最大的成本组成部分。
VL相关的经济成本对社会和患者而言都很高。比哈尔邦的公共卫生当局应专注于早期发现VL并实施干预措施以减轻受VL影响家庭负担的政策。
